{"protocolSection":{"identificationModule":{"nctId":"NCT05005273","orgStudyIdInfo":{"id":"CA020-016"},"secondaryIdInfos":[{"id":"2021-000039-29","type":"EUDRACT_NUMBER"},{"id":"U1111-1263-4850","type":"OTHER","domain":"WHO"}],"organization":{"fullName":"Bristol-Myers Squibb","class":"INDUSTRY"},"briefTitle":"A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer","officialTitle":"A Phase 2 Randomized Study of BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2024-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-10-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-12-27","type":"ACTUAL"},"completionDateStruct":{"date":"2022-12-27","type":"ACTUAL"},"studyFirstSubmitDate":"2021-08-09","studyFirstSubmitQcDate":"2021-08-09","studyFirstPostDateStruct":{"date":"2021-08-13","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-12-15","resultsFirstSubmitQcDate":"2024-01-29","resultsFirstPostDateStruct":{"date":"2024-02-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-01-29","lastUpdatePostDateStruct":{"date":"2024-02-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bristol-Myers Squibb","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to determine the safety and efficacy of BMS-986207 in combination with nivolumab and ipilimumab as first-line treatment for participants with stage IV non-small cell lung cancer (NSCLC)."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"],"keywords":["Non-Small Cell Lung Cancer","NSCLC","BMS-986207","Nivolumab","Opdivo","Ipilimumab","Yervoy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":1,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm A","type":"EXPERIMENTAL","interventionNames":["Drug: Nivolumab","Drug: Ipilimumab","Drug: BMS-986207"]},{"label":"Arm B","type":"EXPERIMENTAL","interventionNames":["Drug: Nivolumab","Drug: Ipilimumab","Other: Placebo"]}],"interventions":[{"type":"DRUG","name":"Nivolumab","description":"Specified dose on specified days","armGroupLabels":["Arm A","Arm B"],"otherNames":["Opdivo","BMS-963558"]},{"type":"DRUG","name":"Ipilimumab","description":"Specified dose on specified days","armGroupLabels":["Arm A","Arm B"],"otherNames":["Yervoy","BMS-734016"]},{"type":"DRUG","name":"BMS-986207","description":"Specified dose on specified days","armGroupLabels":["Arm A"]},{"type":"OTHER","name":"Placebo","description":"Specified dose on specified days","armGroupLabels":["Arm B"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival by BICR","description":"PFS is defined for all randomized participants as the date from randomization to the date of the documentation of disease progression by BICR or death due to any cause, whichever is earlier.\n\nProgressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.","timeFrame":"From first dose to progression or death, 2.3 months"}],"secondaryOutcomes":[{"measure":"Progression Free Survival by Investigator","description":"PFS is defined for all randomized participants as the date from randomization to the date of the documentation of disease progression or death due to any cause, whichever is earlier.\n\nProgressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.","timeFrame":"From first dose to progression or death, 2.3 months"},{"measure":"Overall Response Rate (ORR) by BICR","description":"ORR is defined as the percentage of participants with a confirmed Best overall response of Complete Response (CR) or Partial Response (PR) by RECIST v1.1.\n\nComplete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.\n\nPartial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","timeFrame":"From first dose to progression or death, 2.3 months"},{"measure":"Overall Response Rate (ORR) by Investigator","description":"ORR is defined as the percentage of participants with a confirmed Best overall response of Complete Response (CR) or Partial Response (PR) by RECIST v1.1.\n\nComplete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.\n\nPartial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","timeFrame":"From first dose to progression or death, 2.3 months"},{"measure":"Duration of Response (DOR) by Investigator","description":"DOR is defined for participants who have a confirmed CR or PR as the date from first documented CR or PR per RECIST v1.1 to the date of the documentation of disease progression or death due to any cause, whichever is earlier.\n\nComplete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.\n\nPartial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","timeFrame":"From first dose to progression or death, 2.3 months"},{"measure":"Overall Survival (OS)","description":"OS is defined as the time from randomization to the time of death due to any cause.","timeFrame":"From randomization to time of death, 2.3 months"},{"measure":"Number of Participants Who Had AEs, SAEs, AEs Leading to Discontinuation and Deaths.","timeFrame":"From first dose to progression or death, 2.3 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed metastatic 1L Stage IV non-small cell lung cancer (NSCLC) of squamous or nonsquamous histology\n* No prior systemic anti-cancer treatment given as primary therapy for advanced or metastatic NSCLC\n* Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* A formalin-fixed, paraffin-embedded (FFPE) tumor tissue block or a minimum of 20 unstained slides of tumor tissue obtained during screening or prior to enrollment\n* Life expectancy of at least 3 months at the time of first dose\n\nExclusion Criteria:\n\n* Participants with epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or c-ros oncogene 1 (ROS-1) mutations which are sensitive to available targeted inhibitor therapy. Participants with nonsquamous histology and unknown EGFR, ALK, or ROS-1 status are also excluded\n* Participants with known B-rapidly accelerated fibrosarcoma proto-oncogene (BRAF) V600E mutations that are sensitive to available targeted inhibitor therapy. Participants with unknown or indeterminate BRAF mutation status are eligible.\n* Untreated central nervous system metastases\n* Leptomeningeal metastases (carcinomatous meningitis)\n* Concurrent malignancy requiring treatment\n* Active, known, or suspected autoimmune disease\n* Interstitial lung disease\n* Uncontrolled or significant cardiovascular disease\n\nOther protocol-defined inclusion/exclusion criteria apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Bristol-Myers Squibb","affiliation":"Bristol-Myers Squibb","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Local Institution - 0080","city":"Tucson","state":"Arizona","zip":"85719","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"Local Institution - 0051","city":"Fountain Valley","state":"California","zip":"92708","country":"United States","geoPoint":{"lat":33.70918,"lon":-117.95367}},{"facility":"Local Institution - 0070","city":"Fort Myers","state":"Florida","zip":"33901","country":"United States","geoPoint":{"lat":26.62168,"lon":-81.84059}},{"facility":"Local Institution - 0073","city":"Gainesville","state":"Florida","zip":"32610","country":"United States","geoPoint":{"lat":29.65163,"lon":-82.32483}},{"facility":"Local Institution - 0036","city":"Orange City","state":"Florida","zip":"32763","country":"United States","geoPoint":{"lat":28.94888,"lon":-81.29867}},{"facility":"Local Institution - 0045","city":"Pensacola","state":"Florida","zip":"32504","country":"United States","geoPoint":{"lat":30.42131,"lon":-87.21691}},{"facility":"Local Institution","city":"Port Saint Lucie","state":"Florida","zip":"34952","country":"United States","geoPoint":{"lat":27.29393,"lon":-80.35033}},{"facility":"Local Institution - 0068","city":"St. Petersburg","state":"Florida","zip":"33705","country":"United States","geoPoint":{"lat":27.77086,"lon":-82.67927}},{"facility":"Local Institution","city":"Tallahassee","state":"Florida","zip":"32308","country":"United States","geoPoint":{"lat":30.43826,"lon":-84.28073}},{"facility":"Local Institution","city":"West Palm Beach","state":"Florida","zip":"33401","country":"United States","geoPoint":{"lat":26.71534,"lon":-80.05337}},{"facility":"Local Institution - 0081","city":"Boise","state":"Idaho","zip":"83706","country":"United States","geoPoint":{"lat":43.6135,"lon":-116.20345}},{"facility":"Local Institution - 0077","city":"Coeur d'Alene","state":"Idaho","zip":"83214","country":"United States","geoPoint":{"lat":47.67768,"lon":-116.78047}},{"facility":"Local Institution - 0074","city":"Edgewood","state":"Kentucky","zip":"41017","country":"United States","geoPoint":{"lat":39.01867,"lon":-84.58189}},{"facility":"Local Institution - 0002","city":"Ann Arbor","state":"Michigan","zip":"48109","country":"United States","geoPoint":{"lat":42.27756,"lon":-83.74088}},{"facility":"Local Institution - 0049","city":"Brooklyn","state":"New York","zip":"11220","country":"United States","geoPoint":{"lat":40.6501,"lon":-73.94958}},{"facility":"Local Institution - 0012","city":"Charleston","state":"South Carolina","zip":"29414","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"facility":"Local Institution - 0053","city":"Milwaukee","state":"Wisconsin","zip":"53226","country":"United States","geoPoint":{"lat":43.0389,"lon":-87.90647}},{"facility":"Local Institution - 0009","city":"Pergamino","state":"Buenos Aires","zip":"2700","country":"Argentina","geoPoint":{"lat":-33.89101,"lon":-60.57462}},{"facility":"Local Institution - 0054","city":"Rosario","state":"Santa Fe Province","zip":"S2000DEJ","country":"Argentina","geoPoint":{"lat":-32.94682,"lon":-60.63932}},{"facility":"Local Institution - 0062","city":"Buenos Aires","zip":"1061","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Local Institution - 0021","city":"Buenos Aires","zip":"1125","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Local Institution - 0011","city":"Buenos Aires","zip":"1280","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Local Institution - 0048","city":"Buenos Aires","zip":"C1122","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Local Institution - 0057","city":"San Juan","zip":"5400","country":"Argentina","geoPoint":{"lat":-31.53726,"lon":-68.52568}},{"facility":"Local Institution - 0063","city":"Orange","state":"New South Wales","zip":"2800","country":"Australia","geoPoint":{"lat":-33.28397,"lon":149.10018}},{"facility":"Local Institution - 0056","city":"Wahroonga","state":"New South Wales","zip":"0","country":"Australia","geoPoint":{"lat":-33.71816,"lon":151.11561}},{"facility":"Local Institution - 0052","city":"Warrnambool","state":"Victoria","zip":"3280","country":"Australia","geoPoint":{"lat":-38.38176,"lon":142.48799}},{"facility":"Local Institution - 0034","city":"Mechelen","state":"Antwerpen","zip":"2800","country":"Belgium","geoPoint":{"lat":51.02574,"lon":4.47762}},{"facility":"Local Institution - 0040","city":"Charleroi","zip":"6000","country":"Belgium","geoPoint":{"lat":50.41136,"lon":4.44448}},{"facility":"Local Institution - 0043","city":"Mons","zip":"7000","country":"Belgium","geoPoint":{"lat":50.45413,"lon":3.95229}},{"facility":"Local Institution - 0019","city":"Sint-Niklaas","zip":"9100","country":"Belgium","geoPoint":{"lat":51.16509,"lon":4.1437}},{"facility":"Local Institution - 0035","city":"Viña del Mar","state":"Región de Valparaíso","zip":"2520000","country":"Chile","geoPoint":{"lat":-33.02457,"lon":-71.55183}},{"facility":"Local Institution - 0015","city":"Viña del Mar","state":"Región de Valparaíso","zip":"2520598","country":"Chile","geoPoint":{"lat":-33.02457,"lon":-71.55183}},{"facility":"Local Institution - 0050","city":"Santiago","state":"Santiago Metropolitan","zip":"8320000","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Local Institution - 0037","city":"Limoges","zip":"87042","country":"France","geoPoint":{"lat":45.83362,"lon":1.24759}},{"facility":"Local Institution - 0030","city":"Nantes","zip":"44093","country":"France","geoPoint":{"lat":47.21725,"lon":-1.55336}},{"facility":"Local Institution - 0044","city":"Pessac","zip":"33604","country":"France","geoPoint":{"lat":44.80565,"lon":-0.6324}},{"facility":"Local Institution - 0016","city":"Rouen","zip":"76000","country":"France","geoPoint":{"lat":49.44313,"lon":1.09932}},{"facility":"Local Institution - 0031","city":"Saint-Priest-en-Jarez","zip":"42271","country":"France","geoPoint":{"lat":45.4739,"lon":4.37678}},{"facility":"Local Institution - 0013","city":"Suresnes","zip":"92150","country":"France","geoPoint":{"lat":48.87143,"lon":2.22929}},{"facility":"Local Institution - 0042","city":"Toulon","zip":"83056","country":"France","geoPoint":{"lat":43.12442,"lon":5.92836}},{"facility":"Local Institution - 0005","city":"Gauting","state":"Bavaria","zip":"82131","country":"Germany","geoPoint":{"lat":48.06919,"lon":11.37703}},{"facility":"Local Institution - 0022","city":"Frankfurt am Main","state":"Hesse","zip":"60590","country":"Germany","geoPoint":{"lat":50.11552,"lon":8.68417}},{"facility":"Local Institution - 0017","city":"Gera","zip":"7548","country":"Germany","geoPoint":{"lat":50.88029,"lon":12.08187}},{"facility":"Local Institution - 0023","city":"München","zip":"81925","country":"Germany","geoPoint":{"lat":51.60698,"lon":13.31243}},{"facility":"Local Institution - 0059","city":"Wiesbaden","zip":"65199","country":"Germany","geoPoint":{"lat":50.08601,"lon":8.24435}},{"facility":"Local Institution - 0064","city":"Haifa","zip":"3339419","country":"Israel","geoPoint":{"lat":32.81303,"lon":34.99928}},{"facility":"Local Institution - 0061","city":"Jerusalem","zip":"9103102","country":"Israel","geoPoint":{"lat":31.76904,"lon":35.21633}},{"facility":"Local Institution - 0078","city":"Jerusalem","zip":"91200","country":"Israel","geoPoint":{"lat":31.76904,"lon":35.21633}},{"facility":"Local Institution - 0079","city":"Jerusalem","zip":"91200","country":"Israel","geoPoint":{"lat":31.76904,"lon":35.21633}},{"facility":"Local Institution - 0039","city":"Monza","state":"MB","zip":"20900","country":"Italy","geoPoint":{"lat":45.58005,"lon":9.27246}},{"facility":"Local Institution - 0020","city":"Rozzano","state":"MI","zip":"20089","country":"Italy","geoPoint":{"lat":45.38193,"lon":9.1559}},{"facility":"Local Institution","city":"Milan","zip":"20133","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Local Institution - 0028","city":"Naples","zip":"80131","country":"Italy","geoPoint":{"lat":40.85216,"lon":14.26811}},{"facility":"Local Institution - 0001","city":"Padua","zip":"35128","country":"Italy","geoPoint":{"lat":45.40797,"lon":11.88586}},{"facility":"Local Institution - 0024","city":"Bydgoszcz","zip":"85-796","country":"Poland","geoPoint":{"lat":53.1235,"lon":18.00762}},{"facility":"Local Institution - 0003","city":"Lodz","zip":"93-338","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"Local Institution - 0038","city":"Otwock","zip":"05-400","country":"Poland","geoPoint":{"lat":52.10577,"lon":21.26129}},{"facility":"Local Institution - 0058","city":"Szczecin","zip":"70-452","country":"Poland","geoPoint":{"lat":53.42894,"lon":14.55302}},{"facility":"Local Institution - 0033","city":"Majadahonda","state":"Madrid","zip":"28220","country":"Spain","geoPoint":{"lat":40.47353,"lon":-3.87182}},{"facility":"Local Institution - 0041","city":"Alicante","zip":"3010","country":"Spain","geoPoint":{"lat":38.34517,"lon":-0.48149}},{"facility":"Local Institution - 0026","city":"Barcelona","zip":"08017","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Local Institution - 0075","city":"Barcelona","zip":"08028","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Local Institution - 0006","city":"Barcelona","zip":"08908","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Local Institution - 0046","city":"Jaén","zip":"23007","country":"Spain","geoPoint":{"lat":37.76922,"lon":-3.79028}},{"facility":"Local Institution - 0032","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Local Institution - 0076","city":"Istanbul","zip":"34010","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Local Institution - 0066","city":"Istanbul","zip":"34098","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Local Institution - 0065","city":"Izmir","zip":"35575","country":"Turkey (Türkiye)","geoPoint":{"lat":38.41273,"lon":27.13838}},{"facility":"Local Institution - 0067","city":"Samsun","zip":"55200","country":"Turkey (Türkiye)","geoPoint":{"lat":41.27976,"lon":36.3361}},{"facility":"Local Institution - 0072","city":"Yüreğir","zip":"01250","country":"Turkey (Türkiye)","geoPoint":{"lat":36.97439,"lon":35.35916}}]},"referencesModule":{"seeAlsoLinks":[{"label":"BMS Clinical Trial Information","url":"https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"},{"label":"FDA Safety Alerts and Recalls","url":"https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"},{"label":"BMS Clinical Trial Patient Recruiting","url":"https://www.bmsstudyconnect.com/s/US/English/USenHome"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria.\n\nAdditional information regarding Bristol Myer Squibb's data sharing policy and process can be found at:\n\nhttps://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"See Plan Description","accessCriteria":"See Plan Description","url":"https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"1 participant randomized and treated","groups":[{"id":"FG000","title":"Treatment 1","description":"nivolumab 360mg Q3W Ipilimumab 1mg/kg Q6W BMS-986207 600mg Q3W"},{"id":"FG001","title":"Treatment 2","description":"nivolumab 360mg Q3W Ipilimumab 1mg/kg Q6W Placebo Q3W"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Study Terminated","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"1 participant randomized and treated","groups":[{"id":"BG000","title":"Treatment 1","description":"nivolumab 360mg Q3W Ipilimumab 1mg/kg Q6W BMS-986207 600mg Q3W"},{"id":"BG001","title":"Treatment 2","description":"nivolumab 360mg Q3W Ipilimumab 1mg/kg Q6W Placebo Q3W"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival by BICR","description":"PFS is defined for all randomized participants as the date from randomization to the date of the documentation of disease progression by BICR or death due to any cause, whichever is earlier.\n\nProgressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.","populationDescription":"BICR evaluation did not occur so 0 participants were analyzed for this endpoint.","reportingStatus":"POSTED","timeFrame":"From first dose to progression or death, 2.3 months","groups":[{"id":"OG000","title":"Treatment 1","description":"nivolumab 360mg Q3W Ipilimumab 1mg/kg Q6W BMS-986207 600mg Q3W"},{"id":"OG001","title":"Treatment 2","description":"nivolumab 360mg Q3W Ipilimumab 1mg/kg Q6W Placebo Q3W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Progression Free Survival by Investigator","description":"PFS is defined for all randomized participants as the date from randomization to the date of the documentation of disease progression or death due to any cause, whichever is earlier.\n\nProgressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.","populationDescription":"All Treated Participants","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From first dose to progression or death, 2.3 months","groups":[{"id":"OG000","title":"Treatment 1","description":"nivolumab 360mg Q3W Ipilimumab 1mg/kg Q6W BMS-986207 600mg Q3W"},{"id":"OG001","title":"Treatment 2","description":"nivolumab 360mg Q3W Ipilimumab 1mg/kg Q6W Placebo Q3W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","lowerLimit":"NA","upperLimit":"NA","comment":"1 participant analyzed. Lower limit and upper limit cannot be computed via KM methodology."}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate (ORR) by BICR","description":"ORR is defined as the percentage of participants with a confirmed Best overall response of Complete Response (CR) or Partial Response (PR) by RECIST v1.1.\n\nComplete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.\n\nPartial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","populationDescription":"BICR evaluation did not occur so 0 participants were analyzed for this endpoint.","reportingStatus":"POSTED","timeFrame":"From first dose to progression or death, 2.3 months","groups":[{"id":"OG000","title":"Treatment 1","description":"nivolumab 360mg Q3W Ipilimumab 1mg/kg Q6W BMS-986207 600mg Q3W"},{"id":"OG001","title":"Treatment 2","description":"nivolumab 360mg Q3W Ipilimumab 1mg/kg Q6W Placebo Q3W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Overall Response Rate (ORR) by Investigator","description":"ORR is defined as the percentage of participants with a confirmed Best overall response of Complete Response (CR) or Partial Response (PR) by RECIST v1.1.\n\nComplete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.\n\nPartial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","populationDescription":"0 participants met the criteria for to be considered CR and PR, 0 participants were analyzed for this endpoint","reportingStatus":"POSTED","timeFrame":"From first dose to progression or death, 2.3 months","groups":[{"id":"OG000","title":"Treatment 1","description":"nivolumab 360mg Q3W Ipilimumab 1mg/kg Q6W BMS-986207 600mg Q3W"},{"id":"OG001","title":"Treatment 2","description":"nivolumab 360mg Q3W Ipilimumab 1mg/kg Q6W Placebo Q3W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR) by Investigator","description":"DOR is defined for participants who have a confirmed CR or PR as the date from first documented CR or PR per RECIST v1.1 to the date of the documentation of disease progression or death due to any cause, whichever is earlier.\n\nComplete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.\n\nPartial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","populationDescription":"All Treated Participants","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From first dose to progression or death, 2.3 months","groups":[{"id":"OG000","title":"Treatment 1","description":"nivolumab 360mg Q3W Ipilimumab 1mg/kg Q6W BMS-986207 600mg Q3W"},{"id":"OG001","title":"Treatment 2","description":"nivolumab 360mg Q3W Ipilimumab 1mg/kg Q6W Placebo Q3W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Participant did not meet criteria for CR or PR so could not be evaluated"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS is defined as the time from randomization to the time of death due to any cause.","populationDescription":"All Treated Participants","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From randomization to time of death, 2.3 months","groups":[{"id":"OG000","title":"Treatment 1","description":"nivolumab 360mg Q3W Ipilimumab 1mg/kg Q6W BMS-986207 600mg Q3W"},{"id":"OG001","title":"Treatment 2","description":"nivolumab 360mg Q3W Ipilimumab 1mg/kg Q6W Placebo Q3W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","lowerLimit":"NA","upperLimit":"NA","comment":"only 1 participant treated and analyzed, lower limit number and upper limit number cannot be calculated using KM methodology."}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Had AEs, SAEs, AEs Leading to Discontinuation and Deaths.","populationDescription":"All Treated Participants","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose to progression or death, 2.3 months","groups":[{"id":"OG000","title":"Treatment 1","description":"nivolumab 360mg Q3W Ipilimumab 1mg/kg Q6W BMS-986207 600mg Q3W"},{"id":"OG001","title":"Treatment 2","description":"nivolumab 360mg Q3W Ipilimumab 1mg/kg Q6W Placebo Q3W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"classes":[{"title":"Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Serious Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"AEs leading to discontinuation","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Deaths","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse Events and Serious Adverse Events (From first dose to last dose + 100 days) and All-Cause mortality (From randomization to end of study): 2.3 Months","description":"The number at Risk for All-Cause Mortality represents all Randomized Participants. The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication","eventGroups":[{"id":"EG000","title":"Nivolumab 360 mg + Ipilimumab 1 mg/kg + BMS-986207 600 mg","description":"nivolumab 360mg Q3W Ipilimumab 1mg/kg Q6W BMS-986207 600mg Q3W","deathsNumAffected":1,"deathsNumAtRisk":1,"seriousNumAffected":1,"seriousNumAtRisk":1,"otherNumAffected":1,"otherNumAtRisk":1},{"id":"EG001","title":"Nivolumab 360 mg + Ipilimumab 1 mg/kg + Placebo","description":"nivolumab 360mg Q3W Ipilimumab 1mg/kg Q6W Placebo Q3W","deathsNumAffected":0,"deathsNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"otherNumAffected":0,"otherNumAtRisk":0}],"seriousEvents":[{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1},{"groupId":"EG001","numAffected":0,"numAtRisk":0}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1},{"groupId":"EG001","numAffected":0,"numAtRisk":0}]}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1},{"groupId":"EG001","numAffected":0,"numAtRisk":0}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1},{"groupId":"EG001","numAffected":0,"numAtRisk":0}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1},{"groupId":"EG001","numAffected":0,"numAtRisk":0}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1},{"groupId":"EG001","numAffected":0,"numAtRisk":0}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1},{"groupId":"EG001","numAffected":0,"numAtRisk":0}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1},{"groupId":"EG001","numAffected":0,"numAtRisk":0}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1},{"groupId":"EG001","numAffected":0,"numAtRisk":0}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1},{"groupId":"EG001","numAffected":0,"numAtRisk":0}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Due to 1 participant being randomized and treated sub group analysis were not completed for this study."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."},"pointOfContact":{"title":"Bristol-Myers Squibb Study Director","organization":"Bristol-Myers Squibb","email":"Clinical.Trials@BMS.com","phone":"Please Email"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2022-06-13","uploadDate":"2023-12-15T09:50","filename":"Prot_SAP_000.pdf","size":17145586}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Hungary"],"submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2024-01-09","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077594","term":"Nivolumab"},{"id":"D000074324","term":"Ipilimumab"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"}]}},"hasResults":true}